These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26635138)

  • 1. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device.
    Cohen D
    BMJ; 2015 Dec; 351():h6431. PubMed ID: 26635138
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban: can we trust the evidence?
    Cohen D
    BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 5. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).
    Suzuki S; Yamashita T; Kasai H; Otsuka T; Sagara K
    Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain.
    Escobar Cervantes C
    Future Cardiol; 2018 May; 14(3s):1-2. PubMed ID: 29848088
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous thrombolysis for acute ischemic stroke in a patient receiving rivaroxaban.
    Landais A; Ginoux C
    J Stroke Cerebrovasc Dis; 2015 Mar; 24(3):e73-4. PubMed ID: 25561312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Good efficacy and safety profile in clinical practice].
    MMW Fortschr Med; 2015 Nov; 157(20):66-7. PubMed ID: 26977521
    [No Abstract]   [Full Text] [Related]  

  • 11. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation--The RELIEF study.
    Coleman CI; Antz M; Ehlken B; Evers T
    Int J Cardiol; 2016 Jan; 203():882-4. PubMed ID: 26605688
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivaroxaban for thromboprophylaxis in a patient receiving electroconvulsive therapy.
    Shuman M; Hieber R; Moss L; Patel D
    J ECT; 2015 Mar; 31(1):e19-20. PubMed ID: 25587812
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
    Simonyi G; Medvegy M
    Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 16. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    Cairns JA; Weitz JI
    Am Heart J; 2015 Jan; 169(1):1-3. PubMed ID: 25497240
    [No Abstract]   [Full Text] [Related]  

  • 17. [APPLICATION Rivaroxaban for Secondary Stroke Prevention in Clinical Practice. RESULTS OF RUSSIAN Prospective, Multicenter, Observational Study NEURO-XAR].
    Fonyakin On Behalf Of The Working Group Of Researchers AV
    Kardiologiia; 2016 Apr; 56(4):49-53. PubMed ID: 28294859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option.
    Piotrowski R; Zaborska B; Baran J; Sikora-Frąc M; Kułakowski P
    Pol Arch Med Wewn; 2016 Jun; 126(6):430-1. PubMed ID: 27305139
    [No Abstract]   [Full Text] [Related]  

  • 20. Rivaroxaban in Chronic Hemodialysis Patients.
    Muster H; Alcorn H
    Am J Nephrol; 2016; 43(4):227-8. PubMed ID: 27100995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.